News

MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via

The trial was held in patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who

VE303 is claimed to be the first drug featuring a rationally-defined bacterial consortium to advance to phase 2 study. The earlier announced phase 1a/1b study showed rapid, durable,

Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies

The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemistry

Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer

The product candidates include pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent will pay Incyte US$40m in cash up

Herzuma, which is a HER2/neu receptor antagonist biosimilar to Herceptin, has been approved to treat HER2-overexpressing breast cancer for certain indications. Celltrion CEO Woosung Kee said: “Biosimilars are

Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the Bankruptcy Code) with the US Bankruptcy Court for the Southern District of New